D-Serine: Potential Therapeutic Agent and/or Biomarker in Schizophrenia and Depression?

Frontiers in Psychiatry
Mary-Anne B MacKayGlen B Baker

Abstract

D-Serine is a potent co-agonist at the NMDA glutamate receptor and has been the object of many preclinical studies to ascertain the nature of its metabolism, its regional and cellular distribution in the brain, its physiological functions and its possible clinical relevance. The enzymes involved in its formation and catabolism are serine racemase (SR) and D-amino acid oxidase (DAAO), respectively, and manipulations of the activity of those enzymes have been useful in developing animal models of schizophrenia and in providing clues to the development of potential new antipsychotic strategies. Clinical studies have been conducted in schizophrenia patients to evaluate body fluid levels of D-serine and/or to use D-serine alone or in combination with antipsychotics to determine its effectiveness as a therapeutic agent. D-serine has also been used in combination with DAAO inhibitors in preclinical investigations, and interesting results have been obtained. Genetic studies and postmortem brain studies have also been conducted on D-serine and the enzymes involved in its metabolism. It is also of considerable interest that in recent years clinical and preclinical investigations have suggested that D-serine may also have antidepressant p...Continue Reading

References

Jan 13, 1992·FEBS Letters·A HashimotoK Takahashi
Jan 1, 1990·Advances in Enzyme Regulation·K Snell, D A Fell
Jul 1, 1997·Progress in Neurobiology·A Hashimoto, T Oka
Dec 4, 1998·Biological Psychiatry·G TsaiJ T Coyle
Nov 11, 1999·Proceedings of the National Academy of Sciences of the United States of America·H WoloskerS H Snyder
Oct 5, 2002·Proceedings of the National Academy of Sciences of the United States of America·Ilya ChumakovJohn Realson
Dec 20, 2003·Annals of the New York Academy of Sciences·Joseph T CoyleDonald Goff
Feb 19, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Janne Damm Andersen, Bruno Pouzet
Feb 3, 2005·Proceedings of the National Academy of Sciences of the United States of America·Paul M KimSolomon H Snyder
Apr 1, 2005·Proceedings of the National Academy of Sciences of the United States of America·Jean-Pierre MothetGérard Baux
Jun 9, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Kenji HashimotoMasaomi Iyo
Jun 28, 2005·Molecular Genetics and Metabolism·Sabine A FuchsTom J de Koning
Sep 13, 2005·Biological Psychiatry·Guochuan E TsaiMian-Yoon Chong
Oct 14, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Maria ShleperHerman Wolosker
Nov 30, 2005·Molecular Psychiatry·K FujiiA Sawa
Apr 4, 2006·Biological Psychiatry·Sevilla D Detera-Wadleigh, Francis J McMahon
May 19, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Hideaki MitaniRyuzou Kawahara
May 23, 2006·The Journal of Biological Chemistry·Elena DuminHerman Wolosker
Dec 13, 2006·Schizophrenia Research·Inna BendikovGalila Agam
Feb 13, 2007·Proceedings of the National Academy of Sciences of the United States of America·Asif K MustafaSolomon H Snyder
Sep 21, 2007·The European Journal of Neuroscience·Louise VerrallPhilip W J Burnet
Oct 24, 2007·Molecular Neurobiology·Herman Wolosker
Apr 2, 2008·Schizophrenia Research·Caroline MadeiraRogério Panizzutti
May 30, 2008·Journal of Medicinal Chemistry·Dana FerrarisTakashi Tsukamoto
Jun 2, 2009·Human Molecular Genetics·Viviane LabrieJohn C Roder
Aug 22, 2009·Neuroscience and Biobehavioral Reviews·Viviane Labrie, John C Roder
Sep 30, 2009·Molecular Psychiatry·L VerrallP J Harrison
Mar 4, 2010·Psychopharmacology·Toshiharu ShimazakiShigeyuki Chaki
Jun 4, 2010·Protein Science : a Publication of the Protein Society·Laura CaldinelliLoredano Pollegioni
Jun 15, 2010·Schizophrenia Research·Joshua T KantrowitzDaniel C Javitt
Sep 16, 2010·Nature Reviews. Neuroscience·Giles E Hardingham, Hilmar Bading
Oct 30, 2010·Genes, Brain, and Behavior·L M DeVitoH Eichenbaum
Feb 8, 2011·Neuropharmacology·Viviane LabrieJohn C Roder
Mar 3, 2011·Current Pharmaceutical Design·Dana V Ferraris, Takashi Tsukamoto
Mar 11, 2011·Human Brain Mapping·Diana P PrataPhilip K McGuire

❮ Previous
Next ❯

Citations

Sep 14, 2020·The European Journal of Neuroscience·Tasuku ArakiRyuta Koyama
May 1, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Luis F C MirandaMaria E C Queiroz
Nov 22, 2019·Frontiers in Molecular Biosciences·Kuldeep DhamaSunil Kumar Joshi
Mar 1, 2020·Clinical and Experimental Nephrology·Tomonori KimuraYoshitaka Isaka
Sep 25, 2019·Nutrients·Jacco J A J BastingsSander S Rensen
Oct 8, 2020·International Journal of Molecular Sciences·James M Seckler, Stephen J Lewis
Dec 9, 2020·International Journal of Molecular Sciences·Olga V AverinaVladimir P Chekhonin
Jul 9, 2020·Biochimica Et Biophysica Acta. Proteins and Proteomics·Cindy J LeeJonathan V Sweedler
Apr 30, 2021·Frontiers in Neuroscience·Qiongqiong WuRenrong Wu
May 1, 2021·Journal of Clinical Medicine·Waldemar Kryszkowski, Tomasz Boczek
Jun 1, 2021·Neuropharmacology·David StroebelPierre Paoletti
Jun 21, 2021·Journal of Gastroenterology·Takehito AsakawaMamoru Watanabe
Jul 27, 2021·Frontiers in Aging Neuroscience·Tao LvXiaohua Zhang
Sep 1, 2021·Translational Psychiatry·Agnès EspanaLaurent Groc
Oct 6, 2021·ACS Nano·Lauren A WarningStephan Link

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here